NovaBay Pharmaceuticals recently announced that they have a breakthrough treatment for onychomycosis, more commonly known as nail fungus, with their new Aganocide® compounds. In pre-clinical trals the Aganocide® compounds have demonstrated “potent antifungal activity in an established pre-clinical infected nail model of onychomycosis.”

NovaBay presented the findings at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Philadelphia on the 1st of this month (you can find the abstract here). A key issue in the use of topical medications for toenail fungus treatment and fingernail fungus is the ability of the antifungal agent to be absorbed into the nail well enough to be able to fight the fungus. The success of Aganocide® seems to be it’s ability to squarely address this problem - not only to fight nail fungus infections but to penetrate and absorb sufficiently through the nail to allow it to effectively combat the fungus.

Dr. Behzad Khosrovi, senior vice president of product development at NovaBay, said “This model tests both the penetration of the nail as well as the effectiveness of the compounds against the targeted fungus. What is remarkable is that, after treatment, the Aganocide formulations were able to eradicate the fungi grown on the other side of the nail, hence indicating not only good penetration but a good antifungal activity against T. rubrum, the fungus responsible for onychomycosis commonly known as nail infection.”

You can listen to a webcast on the findings on the NovaBay site here. You’ll need to register to listen and the interesting information comes between minutes 5 and 11 although the whole webcast lasts around 40 minutes.

Aganocide® looks very promising as a new entrant into the area of nail fungus treatment but it will be a little while yet before we see it in the market place. Until then, the research seems also to support the use of combination treatments to increase the effectiveness of topical nail fungus products.